IL125062A - Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases - Google Patents

Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases

Info

Publication number
IL125062A
IL125062A IL12506296A IL12506296A IL125062A IL 125062 A IL125062 A IL 125062A IL 12506296 A IL12506296 A IL 12506296A IL 12506296 A IL12506296 A IL 12506296A IL 125062 A IL125062 A IL 125062A
Authority
IL
Israel
Prior art keywords
inhibition
treatment
pharmaceutical compositions
compositions containing
proliferative diseases
Prior art date
Application number
IL12506296A
Other languages
English (en)
Other versions
IL125062A0 (en
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL125062A0 publication Critical patent/IL125062A0/xx
Publication of IL125062A publication Critical patent/IL125062A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
IL12506296A 1995-12-22 1996-12-19 Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases IL125062A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57795195A 1995-12-22 1995-12-22
US61576096A 1996-03-13 1996-03-13
PCT/US1996/019603 WO1997023478A1 (en) 1995-12-22 1996-12-19 Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
IL125062A0 IL125062A0 (en) 1999-01-26
IL125062A true IL125062A (en) 2003-11-23

Family

ID=27077386

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12506296A IL125062A (en) 1995-12-22 1996-12-19 Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases

Country Status (24)

Country Link
EP (2) EP1019392B1 (da)
JP (1) JP3193725B2 (da)
KR (1) KR100295224B1 (da)
CN (1) CN1326847C (da)
AR (1) AR005152A1 (da)
AT (1) ATE309238T1 (da)
AU (1) AU730194B2 (da)
BR (1) BR9612203A (da)
CA (2) CA2358394C (da)
CZ (1) CZ292791B6 (da)
DE (1) DE69635424T2 (da)
DK (1) DK1019392T3 (da)
ES (1) ES2248826T3 (da)
HK (1) HK1025571A1 (da)
HU (1) HU228352B1 (da)
IL (1) IL125062A (da)
MX (1) MX9804956A (da)
MY (1) MY119007A (da)
NO (1) NO318232B1 (da)
NZ (1) NZ326035A (da)
PL (1) PL185597B1 (da)
SK (1) SK86198A3 (da)
TW (1) TW350844B (da)
WO (1) WO1997023478A1 (da)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
AU3732197A (en) * 1996-07-26 1998-02-20 Schering Corporation Method for preparing substituted 1-piperidinecarboxamide derivatives
US5925757A (en) * 1996-07-26 1999-07-20 Schering Corporation Method for preparing carboxamides
US6040305A (en) * 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5945429A (en) * 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
AU4337497A (en) * 1996-09-13 1998-04-02 Schering Corporation Tricyclic compounds useful as fpt inhibitors
NZ334453A (en) * 1996-09-13 2000-08-25 Schering Corp Tricyclic inhibitors of farnesyl protein transferase
US5994364A (en) * 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
TR199901273T2 (xx) * 1996-09-13 1999-09-21 Schering Corporation Farnezil protein transferaz inhibisyonu i�in yararl� bile�ikler.
US5985879A (en) * 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5958890A (en) * 1996-09-13 1999-09-28 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
CA2266015C (en) * 1996-09-13 2003-12-30 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
IL128929A0 (en) * 1996-09-13 2000-02-17 Schering Corp Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
ATE286044T1 (de) * 1996-09-13 2005-01-15 Schering Corp Trizyklische verbindungen mit farnesyl protein transferase inhibierender wirkung
US6130229A (en) * 1996-10-09 2000-10-10 Schering Corporation Tricyclic compounds having activity as RAS-FPT inhibitors
AU737621B2 (en) * 1997-02-18 2001-08-23 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060434A1 (en) 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US5998620A (en) * 1997-03-25 1999-12-07 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US5760232A (en) * 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
CN1266432A (zh) * 1997-06-17 2000-09-13 先灵公司 用于抑制法呢基蛋白转移酶的双吡啶并环庚烷化合物
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5877177A (en) * 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6576639B1 (en) 1997-06-17 2003-06-10 Schering Corporation Compounds for the inhibition of farnesyl protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US6358968B1 (en) 1997-06-17 2002-03-19 Schering Corporation N-substituted urea inhibitors of farnesyl-protein transferase
IL133446A0 (en) * 1997-06-17 2001-04-30 Schering Corp Novel phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
CA2293706C (en) * 1997-06-17 2008-11-18 Schering Corporation N-substituted urea inhibitors of farnesyl-protein transferase
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6689789B2 (en) 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6051582A (en) * 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6218401B1 (en) 1997-06-17 2001-04-17 Schering Corporation Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
MY126580A (en) * 1997-12-22 2006-10-31 Merck Sharp & Dohme Molecular dispersion composition with enchanced bioavailabity
PE20000042A1 (es) * 1997-12-22 2000-02-17 Schering Corp Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6706883B1 (en) * 1998-07-02 2004-03-16 Schering Corporation Process for producing (8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-B]pyridin-11-YL)-1-piperdine
EP1091954B1 (en) * 1998-07-02 2003-03-12 Schering Corporation Process for producing (8-chloro-3,10-dibromo-6,11-dihydro-5h-benzo 5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidine
US6535820B1 (en) * 1998-08-28 2003-03-18 Schering Corporation Crystalline farnesyl protein transferase compositions and methods for use
EP1131296A2 (en) 1998-11-20 2001-09-12 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
DK1131313T3 (da) * 1998-11-20 2003-03-31 Schering Corp Enantioselektiv alkylering af tricykliske forbindelser
US6372909B1 (en) 1998-11-20 2002-04-16 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US6307048B1 (en) 1998-11-20 2001-10-23 Schering Corporation Enantioselective alkylation of tricyclic compounds
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
CA2429720C (en) * 2000-11-29 2009-12-29 Schering Corporation Tricyclic compounds useful for the inhibition of farnesyl protein transferase
US20040082588A1 (en) * 2002-09-30 2004-04-29 Schering Corporation Methods for treating disorders of calcium homeostasis
EP2189447B1 (en) * 2002-10-03 2011-11-16 Schering Corporation Enantioselective alkylation of tricyclic compounds
DE602004018332D1 (de) 2003-08-07 2009-01-22 Schering Corp Neue farnesylproteintransferaseinhibitoren als antitumormittel
WO2005017160A2 (en) 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
WO2005089496A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
US8293769B2 (en) 2007-05-21 2012-10-23 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20110129549A1 (en) * 2008-04-17 2011-06-02 Liu Julie F Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof
US20110294794A1 (en) * 2008-11-13 2011-12-01 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010144909A1 (en) 2009-06-12 2010-12-16 Novartis Ag Fused heterocyclic compounds and their uses
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US8987275B2 (en) 2010-03-16 2015-03-24 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
JP6290237B2 (ja) 2012-11-28 2018-03-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための組成物および方法
AR094116A1 (es) 2012-12-20 2015-07-08 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de hdm2
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
KR20160072352A (ko) 2014-12-12 2016-06-23 동보씨엠텍산업(주) 저위투입구 믹서로더
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN107530338B (zh) * 2015-04-21 2020-12-01 艾格尔峰生物制药有限公司 包含洛那法尼和利托那韦的药物组合物
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
KR20240135066A (ko) 2017-04-13 2024-09-10 사이로파 비.브이. 항-sirp 알파 항체
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
ATE210652T1 (de) * 1993-10-15 2001-12-15 Schering Corp Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
HU228352B1 (en) 2013-03-28
ATE309238T1 (de) 2005-11-15
CZ292791B6 (cs) 2003-12-17
MX9804956A (es) 1998-09-30
DE69635424D1 (de) 2005-12-15
DK1019392T3 (da) 2006-03-20
EP1380581A1 (en) 2004-01-14
NO982878D0 (no) 1998-06-19
BR9612203A (pt) 1999-07-13
PL185597B1 (pl) 2003-06-30
HUP9903705A2 (hu) 2000-05-28
CA2240846A1 (en) 1997-07-03
WO1997023478A1 (en) 1997-07-03
PL327312A1 (en) 1998-12-07
HUP9903705A3 (en) 2002-04-29
AU730194B2 (en) 2001-03-01
TW350844B (en) 1999-01-21
NO982878L (no) 1998-08-24
CA2240846C (en) 2002-07-16
EP1019392A1 (en) 2000-07-19
CA2358394C (en) 2006-05-02
JPH11501671A (ja) 1999-02-09
HK1025571A1 (en) 2000-11-17
IL125062A0 (en) 1999-01-26
DE69635424T2 (de) 2006-08-03
NO318232B1 (no) 2005-02-21
KR19990076655A (ko) 1999-10-15
CZ193898A3 (cs) 1998-10-14
CN1326847C (zh) 2007-07-18
NZ326035A (en) 2000-01-28
SK86198A3 (en) 1999-02-11
CA2358394A1 (en) 1997-07-03
ES2248826T3 (es) 2006-03-16
MY119007A (en) 2005-03-31
JP3193725B2 (ja) 2001-07-30
AU1331197A (en) 1997-07-17
AR005152A1 (es) 1999-04-14
CN1209127A (zh) 1999-02-24
EP1019392B1 (en) 2005-11-09
KR100295224B1 (ko) 2001-09-17

Similar Documents

Publication Publication Date Title
IL125062A (en) Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases
IL117603A (en) Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases and pharmaceutical compositions containing them
IL117798A0 (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117604A0 (en) Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117602A0 (en) Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117601A0 (en) Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative dieases
HUP9902105A3 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
IL117957A0 (en) Pharmaceutical compositions for the treatment of impotence
EP0707446A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATING NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOM COMPLEXES
IL114877A0 (en) Derivatives of benzothiazepines pharmaceutical compositions containing them and their use
AP2001002270A0 (en) Metalloproteinaise inhibitors pharmaceutical compositions containing them and their pharmaceeutical uses and methods and intermediates useful for their preparation
HUP9702241A3 (en) Use of 2-aminoindan derivatives and pharmaceutical compositions containing them
ZA936964B (en) Pharmaceutical compositions containing derivatives of nomegestrol and their process of manufacture
IL117797A0 (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
ZA9670B (en) Composition and methods for transdermal delivery of acid-lability drugs
HUP9900147A2 (hu) Terápiás szerek és autoimmun betegségek kezelésére alkalmas gyógyszerkészítmények
HUP9903684A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating depression
HU9500386D0 (en) Benzodiazepine derivatives and pharmaceutical compositions containing them
ZA963350B (en) Cycloheaxane compounds process for their preparation and pharmaceutical compositions containing them
IL122651A (en) Zwitterionic polymorphic forms of trovafloxacin their preparation and pharmaceutical compositions containing them
AU4674693A (en) Pharmaceutical composition and method of treatment for serotonin depletion illness
ZA9610735B (en) Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
HK1002865A1 (en) Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL116500A0 (en) Derivatives of avidin-type molecules and pharmaceutical compositions comprising them
GB9617014D0 (en) Purified form of streptogramins its preparation and pharmaceutical composition containing it

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired